GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » Shares Outstanding (Basic Average)

AGIO (Agios Pharmaceuticals) Shares Outstanding (Basic Average) : 56.94 Mil (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Agios Pharmaceuticals's average basic shares outstanding for the quarter that ended in Sep. 2024 was 56.94 Mil.


Agios Pharmaceuticals Shares Outstanding (Basic Average) Historical Data

The historical data trend for Agios Pharmaceuticals's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Shares Outstanding (Basic Average) Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.00 69.00 60.45 54.79 55.65

Agios Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.80 55.93 56.38 56.80 56.94

Agios Pharmaceuticals Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Agios Pharmaceuticals  (NAS:AGIO) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Agios Pharmaceuticals Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Executives
Rahul D. Ballal director 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Washburn Theodore James Jr. officer: Principal Accounting Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James William Burns officer: Chief Legal Officer C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Cecilia Jones officer: Chief Financial Officer C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Brian Goff director, officer: Chief Executive Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens officer: Chief Medical Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jacqualyn A Fouse director C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Kaye I Foster-cheek director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David P Schenkein director, 10 percent owner, officer: Chief Executive Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Tsveta Milanova officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
Jeffrey D Capello director C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Catherine E. Owen director 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Richa Poddar officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Carman Alenson officer: Principal Accounting Officer 88 SIDNEY STREET, CAMBRIDGE MA 02139